Neuroregeneration

Encode Ideas, L.P. Announces the Initiation of Research Coverage on NervGen Pharma Corp.

Monday, September 13, 2021 - 2:00pm

Dover, Delaware--(Newsfile Corp. - September 13, 2021) - Encode Ideas, L.P. Initiates Research on NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF).

Key Points: 
  • Dover, Delaware--(Newsfile Corp. - September 13, 2021) - Encode Ideas, L.P. Initiates Research on NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF).
  • Encode Ideas, L.P., a healthcare focused research firm, announced today it is initiating coverage on NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF).
  • Encode Ideas, L.P. is a healthcare focused research firm, founded in 2019, providing institutional quality research and investment ideas.
  • Encode Ideas, L.P. has been retained by NervGen, Inc. to provide investor awareness and research coverage.

Checkpoint Surgical Expands Peripheral Nerve Care Portfolio with Addition of NeuroShield® Chitosan Nerve Wrap

Thursday, August 12, 2021 - 3:30pm

Checkpoint Surgical, Inc. has announced an expansion of their intraoperative nerve care product line with the introduction of the NeuroShield Chitosan Nerve Wrap.

Key Points: 
  • Checkpoint Surgical, Inc. has announced an expansion of their intraoperative nerve care product line with the introduction of the NeuroShield Chitosan Nerve Wrap.
  • This addition complements Checkpoint Surgicals existing product portfolio, including the companys flagship Checkpoint Nerve Stimulator/Locator, the leading nerve stimulation device for intraoperative nerve protection and repair.
  • With the addition of NeuroShield, Checkpoint takes a significant step toward a more comprehensive intraoperative nerve care solution, said Len Cosentino, CEO of Checkpoint Surgical.
  • Adding a second innovative product platform to our unique nerve stimulation platform fits squarely in our nerve care mission and helps us realize our vision to be the leading research and technology resource for peripheral nerve care surgeons.

Axogen, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference

Thursday, July 22, 2021 - 12:00pm

ALACHUA, Fla. and TAMPA, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present at the Canaccord Genuity 41st Annual Growth Conference.

Key Points: 
  • ALACHUA, Fla. and TAMPA, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present at the Canaccord Genuity 41st Annual Growth Conference.
  • The presentation will be webcast live and can be accessed through the Investors page at www.axogeninc.com .
  • Axogen (AXGN) Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair.
  • The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries.

Axogen, Inc. to Report Second Quarter Financial Results and Host Conference Call on August 4, 2021

Wednesday, July 14, 2021 - 12:00pm

ALACHUA, Fla. and TAMPA, Fla., July 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021 after the market closes.

Key Points: 
  • ALACHUA, Fla. and TAMPA, Fla., July 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021 after the market closes.
  • Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m.
  • Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair.
  • The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries.

Proactive news headlines including Volt Resources, Orthocell, Zelira Therapeutics and Tempus Resources

Monday, June 21, 2021 - 10:43am

Click here

Key Points: 
  • Click here
    Orthocell Ltd's (ASX:OCC) shares jumped this morning after tabling positive nerve regeneration results one year on from a study testing its nerve repair candidate on quadriplegic patients.
  • Click here
    Tempus Resources Ltd (ASX:TMR) (CVE:TMRR) (OTCMKTS:TMRFF) (FRA:4W0) is logging and sampling core at the Elizabeth Gold Project in British Columbia, Canada, in preparation for analysis at SGS laboratories in Vancouver, Canada.
  • Our written and video content is published on Proactive sites that collectively attract up to 10 million views per month.
  • For more information on how Proactive can help you make a difference, email us at action@proactiveinvestors.com

BioAxone BioSciences Announces Notice of Allowance for Self-Delivering RNA Interference for the Treatment of Spinal Cord Injury

Tuesday, June 8, 2021 - 4:00pm

The notice covers the critical patent application (US 16/321,229) for the proprietary method of treatment of spinal cord injury with BA-434, a novel sd-rxRNA compound that targets transient, non-permanent PTEN suppression to promote axon regeneration and reduce paralysis.

Key Points: 
  • The notice covers the critical patent application (US 16/321,229) for the proprietary method of treatment of spinal cord injury with BA-434, a novel sd-rxRNA compound that targets transient, non-permanent PTEN suppression to promote axon regeneration and reduce paralysis.
  • We look forward to continued exploration of the opportunity to allow for axon regeneration to help serve this unmet need of patients with spinal cord injury.
  • BA-434 is BioAxones novel self-delivering RNA interference compound that reduces expression of PTEN, a protein that blocks axon regeneration in adult neurons.
  • Leveraging 20 years of pioneering research in axon regeneration and diseases involving Rho/ROCK signaling, BioAxone has a clinical stage drug (BA-210) and a preclinical program (BA-434) targeting axon regeneration for treatment of spinal cord injury.

Global Nerve Repair and Regeneration Devices Market to Reach $11.8 Billion by 2026

Tuesday, June 8, 2021 - 3:45pm

SAN FRANCISCO, June 8, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Nerve Repair and Regeneration Devices - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, June 8, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Nerve Repair and Regeneration Devices - Global Market Trajectory & Analytics" .
  • Amid the COVID-19 crisis, the global market for Nerve Repair and Regeneration Devices estimated at US$6.6 Billion in the year 2020, is projected to reach a revised size of US$11.8 Billion by 2026, growing at a CAGR of 10% over the analysis period.
  • This segment currently accounts for a 13.8% share of the global Nerve Repair and Regeneration Devices market.
  • The U.S. Market is Estimated at $2.2 Billion in 2021, While China is Forecast to Reach $1.8 Billion by 2026
    The Nerve Repair and Regeneration Devices market in the U.S. is estimated at US$2.2 Billion in the year 2021.

Axogen, Inc. to present at the Jefferies Virtual Healthcare Conference and the JMP Securities Life Sciences Conference

Tuesday, May 18, 2021 - 12:00pm

For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.axogeninc.com .\nAxogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair.

Key Points: 
  • For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.axogeninc.com .\nAxogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair.
  • Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers.
  • Peripheral nerves provide the pathways for both motor and sensory signals throughout the body.
  • The Axogen portfolio of products is available in the United States, Canada, Germany, United Kingdom, Spain, South Korea, and several other countries.\n"

$16.89 Billion Nerve Repair and Regeneration Markets, 2026

Monday, March 29, 2021 - 3:30pm

The Nerve Repair and Regeneration market is predicted to reach $16.89 Billion by 2026 from $8.62 Billion in 2020, at a CAGR of ~11.8% during the forecast period.

Key Points: 
  • The Nerve Repair and Regeneration market is predicted to reach $16.89 Billion by 2026 from $8.62 Billion in 2020, at a CAGR of ~11.8% during the forecast period.
  • Based on product segment neurostimulation and neuromodulation devices segment accounted the largest share in the nerve repair and regeneration market due to the increasing occurrences of peripheral nerve injuries, advance technology in the nerve repair and regeneration, and the benefits of reimbursement policies are the factors enhancing the market growth.
  • The nerve repair and regeneration market, based on end-users the market is segmented into hospitals and clinics and ambulatory surgery centers.
  • Globally, the nerve repair and regeneration market is expanding due to the increasing neurological disorders; emerging technologies in the field of neurological surgeries, increasing elderly population in all over the world are the factors driving the nerve repair and regeneration market.

NervGen Pharma Receives Orphan Designation from the European Medicines Agency for NVG-291 for the Treatment of Spinal Cord Injury

Monday, March 8, 2021 - 1:30pm

"There are currently no approved pharmaceutical treatments for SCI and existing therapies are limited to preventing further injury.

Key Points: 
  • "There are currently no approved pharmaceutical treatments for SCI and existing therapies are limited to preventing further injury.
  • We are especially encouraged by our preclinical data demonstrating NVG-291's potential to facilitate nerve repair and functional recovery following nerve injury.
  • Orphan Designation in the European Union ("EU") is granted by the European Commission based on a positive opinion issued by the EMA Committee for Orphan Medicinal Products.
  • The Company is developing drugs for the treatment of multiple sclerosis, spinal cord injury and Alzheimer's disease.